drug_type
RELEVANT_DRUG
intervention_type
Vaccine
drug_description
Therapeutic cancer vaccine using a recombinant gorilla adenoviral vector encoding HPV16/18 E6/E7 antigens; delivered subcutaneously to prime and expand HPV-specific CD8+ and CD4+ T cells by antigen presentation in dendritic cells.
nci_thesaurus_concept_id
C172914
nci_thesaurus_preferred_term
Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine
nci_thesaurus_definition
An off-the-shelf (OTS) cancer vaccine comprised of a genetically engineered, replication-deficient gorilla-derived adenovirus encoding human papillomavirus (HPV) types 16 and 18 E6/E7 antigens, with potential immunostimulating and antineoplastic activities. Upon administration of gorilla-derived adenovirus expressing HPV-16/18 E6/E7 vaccine PRGN-2009, the adenovirus infects and expresses the HPV-16/18 E6/E7 proteins. The expressed proteins stimulate the host immune system to produce antigen-specific neutralizing antibodies and to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV-16/18 E6/E7 antigens, thereby inducing tumor cell lysis. HPV oncoproteins play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.
drug_mesh_term
Cancer Vaccines
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Replication-deficient gorilla adenoviral vector delivers genes encoding HPV16/18 E6/E7 antigens to antigen-presenting cells, leading to intracellular expression and presentation on MHC I/II, priming and expanding HPV-specific CD8+ cytotoxic and CD4+ helper T cells and inducing antibody responses, which target and lyse HPV16/18 E6/E7–expressing tumor cells.
drug_name
PRGN-2009
nct_id_drug_ref
NCT05996523